

TriMark Publications

July 2014
Volume: TMRBIOM14-0701

BIOMARKER TECHNOLOGY PLATFORMS FOR CANCER DIAGNOSES AND THERAPIES *(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1.	Overview	13
1.1	Statement of Report	13
1.2	About This Report	13
1.3	Scope of the Report	13
1.4	Objectives	14
1.5	Methodology	14
1.6	Executive Summary	15
2.	Introduction to Cancer Biology and the Diagnostic Industry	20
2.1	Biomarkers	20
2.1.1	The Biomarker Market for Cancer and Key Sectors	20
2.1.1.1	The Sector	20
2.1.1.2	The Critical Path Opportunities	20
2.1.1.3	Capital Markets	20
2.1.1.4	Molecular Diagnostics Technology Platforms	21
2.2	Cancer Detection and Treatment Using Biomarkers as a Guide	21
2.2.1	The Problem	23
2.3	Next Generation Sequencing and Biomarker Discovery	25
2.3.1	Second-Generation Sequencing	26
2.3.2	Whole Genome Sequencing (WGS)	26
2.3.3	Epigenomics	26
2.3.4	Bioinformatics and Next Generation Sequencing	27
2.3.5	Third Next Generation Sequencing	27
3.	Market Analysis of the Cancer Biomarkers Space	28
3.1	Scope of This Chapter	28
3.2	The Overall Market Opportunity and Segmentation of the Total Cancer Biomarkers Marketplace	28
3.3	Potential Cancer Biomarker Commercial Applications	32
3.3.1	Market for Routine Tumor Markers	32
3.3.2	PSA Testing Market Size	39
3.3.3	Market Size and Forecasts for Companion Diagnostic Tests for Cancer Therapeutics	41
3.3.4	SWOT Analysis of the Major Cancer Biomarker Market Segments	44
3.3.4.1	Traditional Serum Cancer Biomarkers	44
3.3.4.2	Proteomic Cancer Biomarkers	44
3.3.4.3	Companion Diagnostic Cancer Biomarkers	45
3.4	Cancer Biomarker Market Estimates by Tissue of Origin	46
3.4.1	Colorectal	47
3.4.2	Prostate	47
3.4.3	Lung	48
3.4.4	Breast	48
3.4.5	Ovarian	49
3.5	Challenges Facing Cancer Biomarker Developers	49
3.6	Unmet Product Needs in the Cancer Biomarkers Space	51
3.7	Epigenic Markers for Cancer	56
3.8	Molecular Diagnostics Testing for Cancer	56
3.9	Market Opportunities	57
3.9.1	Industry Overview	57
3.9.2	Medical Indications and Medically Useful Information	59
3.9.3	Research Market	61
3.9.4	Competition	61
3.9.5	Diagnostic Services	61
3.9.6	Clinical Image Analysis	61
3.9.7	Research Imaging Market	61
3.9.8	Genomic Disease Management and <i>In Vitro</i> Diagnostic Multivariate Index Assays (IVDMIA)	62

3.9.9	Predictive Expression Profiles	63	
4.	Major Clinical Applications of Cancer Biomarkers	64	
4.1	Launched Products and Pipeline	64	
4.2	Launched Products and Pipeline	66	
4.3	CYP2C9 Pharmacogenetics and Role in Personalized Medicine	71	
4.4	Personalized Breast Cancer Therapy	72	
4.5	Personalized NSCLC Therapy	72	
4.6	AmpliChip-Based Personalized Medicine	72	
5.	Breast Cancer	74	
5.1	Overview of Breast Cancer Disease	74	
5.2	Incidence and Mortality Rates	74	
5.2.1	Incidence Rates	74	
5.2.2	Mortality Rates	75	
5.3	BRCA1 and BRCA2 Genes	76	
5.3.1	Types of Genetic Testing Available for Breast Cancer	79	
5.3.1.1	DNA Sequencing	79	
5.3.1.2	Multi-Site Analysis	79	
5.3.1.3	Single-Site Analysis	79	
5.3.2	BRCA Test Results	79	
5.3.2.1	What Does a Positive BRCA1 or BRCA2 Test Result Mean?	79	
5.3.2.2	What does a Negative BRCA1 or BRCA2 Test Result Mean?	80	
5.3.2.3	What does an Ambiguous BRCA1 or BRCA2 Test Result Mean?	80	
5.3.2.4	What are the Options for a Person who Tests Positive?	80	
5.3.3	What are Some of the Benefits of Genetic Testing for Breast Cancer Risk?	81	
5.3.4	What are Some of the Risks of Genetic Testing for Breast and Ovarian Cancer Risk?	81	
5.4	Estrogen Receptors and Breast Cancer	81	
5.4.1	Expression and Prognostic Value of ER	82	
5.4.2	Progesterone Receptors and Breast Cancer	82	
5.4.3	ER and PR Predict Response to Endocrine Therapy	83	
5.5	HER2 Gene and Protein	83	
5.5.1	HER2 Tests	83	
5.5.1.1	IHC Test	84	
5.5.1.2	FISH Test	84	
5.5.1.3	Questions About Testing	86	
5.5.1.4	HER2 Tumor Status	87	
5.6	Herceptin Treatment	87	
5.7	Tumor Assays for Adjuvant Chemotherapy	89	
5.8	Use of Genomics to Understand Breast Cancer	90	
5.9	Genetic Analysis Solution	91	
5.9.1	The Use of Proteomics in Breast Cancer	93	
5.9.2	Tissue Microarrays	95	
5.9.3	Protein Microarrays	97	
5.10	Gene Expression Microarrays and Recurrence Prediction	98	
5.10.1	Oncotype DX	98	
5.10.2	Oncotype DX for Breast Cancer	99	
5.10.3	Risk Assessment	99	
5.10.4	Use of Chemotherapy	100	
5.10.5	Utility of the Oncotype DX Test	100	
5.10.6	Clinical Development and Validation of Oncotype DX	100	
5.10.6.1	Clinical Development of the Oncotype DX Recurrence Score	100	
5.10.6.2	Clinical Validation of Prediction of Recurrence and Survival in N-, ER+ Patients Treated with Tamoxifen	101	
5.10.6.3	Oncotype DX Predicts the Likelihood of Recurrence	101	
5.10.6.4	Oncotype DX Predicts the Likelihood of Breast Cancer Survival in a Community Hospital Setting	102	

5.10.6.5	Oncotype DX Predicts both Prognosis and Tamoxifen Benefit	102
5.11	Economic Benefits of Oncotype DX	103
5.12	Increased Clinical Utility of Oncotype DX	104
5.13	Second Generation Oncotype DX	104
5.13.1	Recurrence and Benefit Test for N-, ER- Breast Cancer	104
5.13.2	Taxane Benefit Test	104
5.14	MammaPrint	104
5.15	Rotterdam Signature 76-Panel	105
5.16	Summary of Microarray Technologies	106
5.17	Mass Spectrometry-Based Approaches	106
5.17.1	Gel-Based Approaches	106
5.17.2	Non-Gel-Based Approaches	107
5.17.2.1	SELDI-TOF MS	108
5.17.2.2	SELDI and Prognosis	109
5.17.2.3	SELDI and Treatment Monitoring	109
5.18	Outlook	111
5.19	Future Perspectives	113
5.20	Breast Cancer Program (NMP66)	114
5.21	Myriad Genetics	114
5.22	Janssen Diagnostics, LLC GeneSearch Breast Lymph Node	115
5.23	OncoVue® Cancer Risk Test (InterGenetics, Inc.)	115
5.24	Research Biomarkers for Breast Cancer	116
5.25	Protein Biomarkers for Breast Cancer Prevention	117
5.26	Biomarker Prognosis of Breast Cancer Treated with Doxorubicin	117
6.	Ovarian Cancer	118
6.1	Incidence Rates	118
6.1.1	Incidence Rates	118
6.1.2	Mortality Rates	119
6.2	Serum Markers	121
6.3	Biomarkers	122
6.3.1	Strategies for Discovering New Cancer Biomarkers	123
6.4	Serum Protein Biomarkers for Ovarian Cancer	123
6.4.1	Clinical Proteomics	124
6.5	Ovarian Cancer Triage Testing	125
6.5.1	Vermillion's Ovarian Cancer Triage Diagnostic Program	126
7.	Prostate Cancer	128
7.1	Overview	128
7.1.1	Incidence Rates	128
7.1.2	Mortality Rates	128
7.1.3	Prostate Cancer Progression and Recurrence Test	128
7.1.4	Current Market Size	129
7.2	Genes Involved in Prostate Cancer	130
7.3	Androgen Independence	131
7.4	Gene Markers in Prostate Cancer	131
7.5	Microarray Gene Identification of Prostate Biomarkers	132
7.6	GEArray DNA Microarrays	134
7.7	Vermillion's Cancer Diagnostic Program	135
7.8	Hepsin	135
7.9	Hologic Gen-Probe's PCA3 Assay	135
7.10	Early Prostate Cancer Antigen-2 (EPCA-2)	136
7.11	New and Novel Methods for Detection of Prostate Cancer	137
7.12	Mass Spectrometry	137
7.13	Summary	139

8.	Bladder Cancer	140
8.1	Overview	140
8.2	Incidence and Mortality Rates	140
8.2.1	Incidence Rates	140
8.2.2	Mortality Rates	140
8.3	Progression and Recurrence	140
8.3.1	Bladder Cancer Risk Factors	141
8.3.2	Bladder Cancer Symptoms	141
8.4	Bladder Cancer Tests	141
8.5	UroVysion Bladder Cancer Kit (Abbott Molecular)	142
8.6	The <i>onco</i> FISH Bladder (Ikonisys)	142
8.6.1	The CellOptics Platform (Ikonisys)	142
8.6.2	Cell Staining and Genetic Characterization	143
8.6.3	Ikoniscope/IkoniLAN Automated Microscopy	143
8.7	Nuclear Matrix Protein Markers	143
8.8	ImmunoCyt/uCyt+	146
8.9	Bladder Cancer Market	147
8.9.1	Urologist Market	147
8.9.2	Clinical Lab Market	147
8.9.3	Primary Care Market	147
8.9.4	Private and Public Sector Markets	148
8.9.5	POC Market	148
8.9.6	Market Distribution	150
8.9.7	Reimbursement	151
9.	Colorectal Cancer	152
9.1	Overview	152
9.2	Incidence and Mortality Rates	152
9.2.1	Incidence Rates	152
9.2.2	Mortality Rates	152
9.2.3	Progression and Recurrence	152
9.3	Screening for CRC	154
9.3.1	Stool-Based DNA Screening	155
9.4	Almac Diagnostics DSA	156
9.5	Colon Cancer Program (NMP35)	157
9.6	Myriad Genetics COLARIS AP Risk Assessment	158
9.7	Summary	158
10.	Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing	159
10.1	Overview	159
10.1.1	Clinicians' Need for More Information with Regard to Therapeutic Treatment Drives Demand for Pharmacogenomic Testing	159
10.1.2	Predictive Medicine Shows Potential for Genetic Diagnostics	159
10.1.3	Different Rates of Growth	160
10.1.4	Effective Competitive Strategies	160
10.1.5	Improvements in Marketing Effectiveness	160
10.1.6	Emerging Technologies Imply Start of a New Era and Offer Tremendous Growth Opportunities	161
10.1.7	Increased Market Share	161
10.1.8	Technologies Used in Genetic Testing	161
10.2	AMAS Test	161
10.3	Corixa (now GSK) Antibodies as Tumor Markers	161
10.4	CytoVision	162
10.5	Ariol System	162
10.6	Mammaglobin Protein Expression	162
10.7	L523S or KOC RNA Binding Protein	163
10.8	CA1-18 from EDP Biotech Corporation	163

11.	Leukemia Biomarkers	164	
11.1	Overview	164	
11.2	Incidence and Mortality Rates	164	
11.2.1	Incidence Rates	164	
11.2.2	Mortality Rates	164	
11.3	Progression and Recurrence	164	
12.	Lung Cancer	166	
12.1	Introduction	166	
12.2	Incidence and Mortality Rates	166	
12.2.1	Incidence Rates	166	
12.2.2	Mortality Rates	166	
12.3	Lung Cancer Diagnostic Tests	167	
13.	Enabling Technologies for Oncology Biomarker Discovery	168	
13.1	Automated Cellular Imaging System (ACIS III)	168	
13.1.1	ACIS for HER2 Protein Expression Testing	169	
13.1.2	ACIS for ER Protein Expression Testing	169	
13.1.3	ACIS for PR Protein Expression Testing	170	
13.1.4	ACIS for Cell Proliferation Expression	170	
13.1.5	ACIS for Protein Expression	170	
13.1.6	ACIS for Protein Micrometastases in Bone Marrow	170	
13.1.7	ACIS for Protein Micrometastases in Tissue	170	
13.1.8	ACIS for TMA	170	
13.1.9	ACIS for DNA Ploidy	170	
13.1.10	ACIS for HPV	171	
13.2	DNA Methylation	171	
13.2.1	Differential Methylation Hybridization (DMH)	171	
13.2.2	MIRA-Assisted Microarrays for DNA Methylation Analysis and Cancer Diagnosis	172	
13.3	Proteomics	172	
13.3.1	Proteomics Technologies for Cancer Marker Discovery	172	
13.3.2	Validation of Candidate Biomarkers	173	
13.3.3	Requirements Bringing a New Marker into the Market	173	
13.3.4	Value Chain in the Development of New Cancer Biomarkers	174	
13.4	Secreted Proteins as Cancer Biomarkers	174	
13.4.1	Markers of Known Tissue Origin	174	
13.4.2	Secreted Proteins as Low Abundance Markers	174	
13.4.3	Secreted Proteins in Tissue and Blood	175	
13.5	Non-coding RNAs as Potential Tumor Markers	175	
13.5.1	miRNA Meets Microarray	175	
13.5.2	Mimetics and Inhibitors	176	
13.5.3	Clinical Patterns in Cancer	176	
13.6	Architect TIMP-1 (Tissue Inhibitor of Metalloproteinases-1) Immunoassay for CRC Detection	176	
13.7	Companies Developing Automated Microscope-Based Analysis Systems	176	
13.8	Companies Developing Research Products for Tumor Cell Isolation	176	
13.9	Companies Supplying Fluorescently Labeled Antibodies to Characterize Tumor Cells	176	
13.10	PerkinElmer High-Throughput Platforms: AlphaScreen, AequoScreen, DELFIA and LANCE Technologies	177	
14.	Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics	178	
14.1	Sector Overview	178	
14.2	Companion Diagnostics	180	
14.3	EGFR for CRC and Camptostar (Irinotecan)	180	
14.3.1	Companion Diagnostic Test Developed for UGT1A1 for Irinotecan	180	
14.3.2	Companion Diagnostic Test Developed for Bristol-Myers' SPRYCEL	181	

14.3.3	EGFR Express and Erbitux (Cetuximab)	181	
14.4	Companions Based on Myriad's IVDMA Technology	181	
14.4.1	Myriad's TheraGuide 5-Fluorouracil (5-FU)	181	
14.4.2	BRACAnalysis Test	182	
14.5	Companions for Tyrosine Kinase Inhibitors: Erlotinib and Gefitinib	183	
14.5.1	TheraScreen: EGFR29	183	
14.5.2	The K-RAS Mutation Detection Kit	183	
14.8	Drivers and Barriers to Companion Diagnostics	183	
14.9	Partnerships with Pharma Companies to Identify Therapeutic Targets	184	
14.10	Future Developments for Companion Diagnostics	185	
15.	Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends	187	
15.1	Scope of This Chapter	187	
15.2	Introduction to Companion Diagnostics and Personalized Medicine	187	
15.2.1	Stakeholders in Companion Diagnostics	187	
15.2.2	Development of Stakeholders' Business Models for Companion Diagnostics for Personalized Medicine	189	
15.2.2.1	Pharmaceutical Company Business Models for Developing Companion Diagnostics Products	189	
15.2.2.2	Diagnostic Company Business Models for Developing Companion Diagnostics Products	190	
15.2.2.3	Life Science Company Business Models for Developing Companion Diagnostics Products	190	
15.2.2.4	Pharmacy Benefit Management Company Business Models for Developing Companion Diagnostics Products	191	
15.2.3	Trends in Companion Diagnostic Deals	192	
15.2.3.1	Market Size of Companion Diagnostics	193	
15.2.4	Companion Diagnostics: Industry SWOT Analysis	200	
15.2.5	Challenges for Companion Diagnostics Development	200	
15.2.6	Timeline for Impact of Various Segments in Companion Diagnostics	202	
15.2.7	Use of Proteomics to Develop Individualized Tests	204	
15.3	The Compelling Case for Personalized Medicine	206	
15.4	Drug Metabolism and Implications for Companion Diagnostics and Personalized Medicine	207	
15.5	Examples of Personalized Medicine	211	
15.6	Personalized Medicine and Companion Diagnostics Testing Product Pipeline	215	
15.7	The Personalized Medicine Coalition	216	
15.8	Regulatory Trends and Guidelines in the Personalized Medicine Space	221	
15.8.1	The Changing Regulatory Landscape for Personalized Medicine	222	
15.9	Patenting Personalized Medicine	223	
15.10	The Leading Edge of Personalized Medicine: Specific Examples of Clinical Situations Where Personalized Medicine and Companion Diagnostics are Appropriate and Being Deployed	226	
15.10.1	EGFR Assay	226	
15.10.2	UGT1A1 Molecular Assay for Camptosar	227	
15.10.3	Response to Gleevec in Gastrointestinal Stromal Tumors	227	
15.10.4	LabCorp and Qiagen and Personalized Medicine for the treatment of Colorectal Cancer	227	
15.10.5	Labcorp and ARCA Discovery, Inc. and Personalized Medicine for Cardiovascular Disease	228	
15.11	Companion Diagnostics and Personalized Medicine: Qualitative and Quantitative Market Analysis	228	
15.11.1	Market Analysis of Molecular Diagnostics and Companion Diagnostics and Personalized Medicine	229	
15.11.2	Diagnostics vs. Pharmaceuticals	230	
15.11.3	Molecular Diagnostic Market	230	
15.11.4	Molecular Diagnostics Technology Platforms and their Impact on Personalized Medicine	233	
15.12	Snapshot of Companion Diagnostics Industry Structure	235	
15.13	The Case for Theranostics (Therapeutic/Companion Diagnostic)	236	
15.14	Personalized Medicine Market Analysis—Market Survey Data Characterizing the Qualitative and Quantitative Industry Parameters	237	
15.15	How the Market Segregates Today	238	

15.16	Timeline for Impact of Various Segments in Personalized Medicine	239	
15.17	Challenges for Personalized Therapeutics and Companion Diagnostics Development		241
15.18	Macro Trends in Personalized Medicine	242	
15.19	Personalized Medicine and Companion Diagnostics: Industry SWOT Analysis		245
16.	Business Trends in the Industry	247	
16.1	Industry Consolidation	247	
16.2	Breadth of Product Offering and Pricing	248	
16.3	Government Regulation of Medical Devices	248	
16.3.1	FDA Guidance on Drug Test Co-Development	250	
16.4	Strategic Business and Marketing Considerations	250	
16.5	Commercial Opportunities in Cancer Markers	251	
16.5.1	Licensing and Intellectual Property Constraints and how they will Impact New Product Development	252	
16.6	Moderators of Growth	252	
16.6.1	Roadblocks to Integrating Cancer Biomarkers into Clinical Practice		253
16.7	Biotechnology Industry Trends	253	
16.8	Pharmaceutical Industry Trends	254	
16.9	Sales and Marketing Strategies for Tumor Marker Tests		254
16.9.1	North American Market	255	
16.9.2	International Markets	256	
16.9.2.1	Europe	256	
16.9.2.2	Central and South America	257	
16.9.2.3	Asia-Pacific	257	
16.10	Product Commercialization	258	
16.11	Reimbursement	259	
16.12	Self Referral Rules	260	
16.13	Health Insurance Portability and Accountability Act		261
16.14	Clinical Laboratory Improvement Amendments	261	
16.15	<i>In Vitro</i> Diagnostic Directive and Medical Device Regulations		262
16.16	FDA's Quality System Regulation	262	
16.17	FDA's OIVD on IVDMIAs	263	
16.18	FDA Approval Process for Protein-Based Biomarkers	264	
16.18.1	Classification of Protein-Based Biomarker Assays as Medical Devices		264
16.18.2	Clinical and Analytical Requirements for Biomarker Performance		265
16.18.3	Approval Process Workflow	267	
16.19	Genetic Tests and Medical Records	267	
16.19.1	Laws Against Genetic Discrimination	268	
16.20	Medicare Reimbursement	269	
16.20.1	Medicare Spending Trends	269	
16.21	Global Drivers of Clinical Laboratory Testing	271	
16.22	Global Outlook for Cancer Biomarkers	271	
16.22.1	Which Companies are Utilizing Cutting-Edge Technologies to Develop, Validate and Implement Cancer Biomarkers for Clinical Use?	272	
16.22.2	What Impediments Still Exist to Incorporating Promising Research into Clinical Practice?		272
16.22.3	Which Biomarkers Show the Most Promise for Approval?	273	
16.22.4	How can Regulatory Oversight Drive Approval and Adoption of New Technologies?	273	
16.22.5	Which Alliances Show the Greatest Synergy in Bringing Valid Biomarkers to Market?	273	
16.22.6	Which Shared Technologies are Driving the Most Encouraging Development?	273	
16.22.7	How Strategic Alliances and Interdisciplinary Involvement Drive Development and Implementation of Emerging Biomarker Technologies	274	
16.23	Oncology Biomarker Qualification Initiative	274	
16.24	FDA Critical Path	275	
16.25	FDA Criteria for a Valid Biomarker	275	
17.	Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms		276

17.1	Abbott Diagnostics	276	
17.2	Affymetrix, Inc.	279	
17.3	Agendia BV	286	
17.4	Agensys, Inc. (Astellas Pharma US)		288
17.5	Agilent Technologies	289	
17.6	Almac Group	290	
17.7	AMDL, Inc.	292	
17.8	Asuragen, Inc.	293	
17.9	Aureon Laboratories, Inc.		294
17.10	Beckman Coulter, Inc.	295	
17.11	Biocode Hycel S.A.	299	
17.12	BioCurex, Inc.	299	
17.13	Biomarker Technologies, LLC	300	
17.14	Biomedical Diagnostics, LLC	300	
17.15	Biomerica, Inc.	301	
17.16	bioMérieux	302	
17.17	Biomira, Inc. (Oncothyreon, Inc.)		303
17.18	Biomoda, Inc.	303	
17.19	Bruker Daltonics, Inc.	304	
17.20	Byk Gulden	305	
17.21	Cangen Biotechnologies, Inc.	305	
17.22	Caprion Proteomics	306	
17.23	Celera Diagnostics	309	
17.24	Cepheid	309	
17.25	Clariant, Inc. (GE Healthcare)	311	
17.26	Claros Diagnostics, Inc.	312	
17.27	Clinical Data, Inc.: PGxHealth and Cogenics		312
17.28	Correlogic Systems, Inc.	314	
17.29	CytoCore, Inc. (Formerly Molecular Diagnostics, Inc.)		315
17.30	Cytogen Corporation (now EUSA Pharma)		316
17.31	Dako (Agilent Technologies)	318	
17.32	diaDexus, LLC	319	
17.33	DiagnoCure, Inc.	320	
17.34	DRG International, Inc.	322	
17.35	EDP Biotech Corporation		323
17.36	Eisai Co., Ltd.	324	
17.37	Eli Lilly & Co.	324	
17.38	Epigenomics	325	
17.39	Exact Sciences Corporation	326	
17.40	Exagen Diagnostics, Inc.	326	
17.41	Exigon	327	
17.42	Gene Logic, Inc.	327	
17.43	Genesis Genomics, Inc. (Mitomics)		328
17.44	GenMark Diagnostics	329	
17.45	Genomic Health, Inc.	330	
17.46	Gen-Probe, Inc. (now known as Hologic Gen-Probe)		331
17.47	Health Discovery Corporation	336	
17.48	Ikonisys, Inc.	337	
17.49	Illumina	337	
17.50	Immunomedics, Inc.	339	
17.51	Incyte Pharmaceuticals, Inc.	341	
17.52	InterGenetics, Inc.	341	
17.53	Ipsogen (Qiagen Marseille)	341	
17.54	Janssen Diagnostics	342	
17.55	LabCorp	343	
17.56	Life Technologies Corporation (Thermo Fisher Scientific)		344

17.57	Matritech, Inc. (Alere)	347
17.58	Miraculins, Inc.	348
17.59	Mitsubishi Kagaku Medical	349
17.60	MolecularMD	349
17.61	Myriad Genetics, Inc.	350
17.62	NimbleGen Systems, Inc.	355
17.63	Northwest Biotherapeutics, Inc.	355
17.64	Oncotech, Inc. (Exiqon A/S)	356
17.65	Oncothyreon, Inc. (Formerly known as Biomira)	357
17.66	OPKO Health, Inc.	359
17.67	Orion Genomics	361
17.68	Oxford BioTherapeutics (Formerly Oxford Genome Sciences)	362
17.69	Panacea Pharmaceuticals, Inc.	363
17.70	Polymedco, Inc.	363
17.71	Power3 Medical Products	364
17.72	Qiagen N.V.	364
17.73	Roche Molecular Diagnostics	368
17.74	SensiGen, LLC (Sequenom Center for Molecular Medicine)	370
17.75	Siemens Healthcare Diagnostics, Inc.	371
17.76	Upstream Biosciences, Inc.	372
17.77	Ventana Medical Systems, Inc. (Part of the Roche Group)	373
17.78	Veridex, LLC (Janssen Diagnostics, LLC)	374
17.79	Vermillion, Inc. (Formerly CIPHERGEN)	375
Appendix 1: Cancer Biomarker Centers of Research		377
Appendix 2: Myriad Patents on Genes BRCA-1 and BRCA-2		378
Appendix 3: Cancer Markers Currently in Common Clinical Use		379
Appendix 4: International Federation of Gynecology and Obstetrics (FIGO) Staging System for Primary Carcinoma of the Ovary		380
Appendix 5: FDA Guidance for Industry: Pharmacogenomic Data Submission		381
A5.1	Introduction	381
A5.2	Background	381
A5.3	Submission Policy	382
A5.3.1	General Principles	382
A5.3.2	Specific Uses of Pharmacogenomic Data in Drug Development and Labeling	384
A5.3.3	Benefits of Voluntary Submissions to Sponsors and FDA	385
A5.4	Submission of Pharmacogenomic Data	386
A5.4.1	Submission of Pharmacogenomic Data During the IND Phase	386
A5.4.2	Submission of Pharmacogenomic Data to a New NDA, BLA or Supplement	387
A5.4.3	Submission to a Previously Approved NDA or BLA	388
A5.4.4	Compliance with 21 CFR Part 58	388
A5.4.5	Submission of Voluntary Genomic Data from Application-Independent Research	388
A5.5	Format and Content of a VGDS	389
A5.6	Process for Submitting Pharmacogenomic Data	390
A5.7	Agency Review of VGDSs	390
Appendix 6: E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions		392
A6.1	Introduction	392
A6.2	Background	392
A6.3	Scope	392
A6.4	General Principles	392
A6.5	Structure of Biomarker Qualification Submissions	393
Glossary		400

INDEX OF FIGURES

Figure 3.1: Potential Market for Cancer Biomarkers	28
Figure 3.2: Segmentation of the Cancer Biomarkers Marketplace Based on Commercial Offerings—Products and Services	31
Figure 3.3: Geographical Distribution of Cancer Tumor Diagnostic Testing	35
Figure 3.4: Cancer Biomarkers Research Market, 2006-2016	43
Figure 3.5: Breast Cancer Biomarker Market Potential, 2010	49
Figure 3.6: Challenges in the Study or Utilization of Proteomic Cancer Biomarkers	50
Figure 3.7: Challenges in the Study or Utilization of Companion Diagnostic Cancer Biomarkers	50
Figure 3.8: Challenges in the Study or Utilization of Serum Cancer Markers	51
Figure 3.9: Top Unmet Needs in Commercial Products in the Cancer Biomarkers Space	52
Figure 5.1: Hybridization Process	85
Figure 5.2: FISH Test Procedure	85
Figure 5.3: Gene Expression Profiling	96
Figure 15.1: Strategic and Tactical Considerations for Co-Development of Companion Diagnostics	192
Figure 15.2: Global Market for Companion Diagnostics	193
Figure 15.3: Number of Companion Diagnostic Agreements, 2000-2013	194
Figure 15.4: Surface Binding Produces Phase Shifts that Increases the Diffraction Signal Intensity	205
Figure 15.5: Phase I and II Processes of Drug Metabolism	207
Figure 15.6: Human Phase I Enzymes	208
Figure 15.7: Human Phase II Enzymes	208
Figure 15.8: Hepatic Distribution of Human CYP450	209
Figure 15.9: Relative Contribution of CYP450 Enzymes to Drug Metabolism	209
Figure 15.10: Genetic Components Determine Drug Metabolism	210
Figure 15.11: From Genetic Content to Personalized Medicine	229
Figure 15.12: Remuneration for Diagnostics	230
Figure 15.13: Breakout of the Molecular Diagnostics Marketplace	231
Figure 15.14: Molecular Diagnostics Market Segmentation	232
Figure 15.15: Molecular Diagnostics Market Segmentation by Technology	233
Figure 15.16: Market Survey Respondent Demographics	237
Figure 15.17: Breakout of the Respondent Pool by Affiliation	238
Figure 15.18: Segmentation of the Personalized Medicine Market	238
Figure 15.19: Personalized Medicine Market Drivers	242
Figure 15.20: Challenges in the Personalized Medicine Space	243
Figure 16.1: Medicare Spending on Clinical Laboratory Services per Enrollee, 2003-2016	269

INDEX OF TABLES

Table 2.1: Cancer Biomarker Stakeholders	23
Table 3.1: Characteristics of Different Cancer Biomarker Types and Associated Market Opportunities	30
Table 3.2: Segmentation of the Cancer Biomarker Market by Type/Lineage of Cancer Biomarkers and Market Size	31
Table 3.3: <i>In Vitro</i> Cancer Marker Market Segments Worldwide, 2007-2012	32
Table 3.4: Worldwide Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2009-2019	33
Table 3.5: U.S. Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2009-2019	33
Table 3.6: Worldwide <i>In Vitro</i> Cancer Tumor Marker Diagnostics Market Size, 2009-2019	34
Table 3.7: U.S. <i>In Vitro</i> Cancer Tumor Marker Diagnostics Market Size, 2009-2019	34
Table 3.8: Japanese <i>In Vitro</i> Cancer Tumor Marker Diagnostics Market Size, 2009-2019	34
Table 3.9: European <i>In Vitro</i> Cancer Tumor Marker Diagnostics Market Size, 2009-2019	35
Table 3.10: Global Distribution of IVD Cancer Tumor Marker Diagnostic Testing, 2013	35
Table 3.11: Estimated Market Share of Major Competitors in U.S. Cancer Tumor Marker Diagnostics Market	36
Table 3.12: Major Presence in Cancer Tumor Marker Diagnostics Markets	36

Table 3.13: Worldwide CEA Sales, 2009-2019	37	
Table 3.14: U.S. CEA Sales, 2009-2019	37	
Table 3.15: Japan CEA Sales, 2009-2019	38	
Table 3.16: Europe CEA Sales, 2009-2019	38	
Table 3.17: Rest of the World CEA Sales, 2009-2019	38	
Table 3.18: Worldwide PSA Sales 2009-2019	39	
Table 3.19: U.S. PSA Sales 2009-2019	40	
Table 3.20: Cancer Biomarkers Research Market Forecast, 2006-2016	42	
Table 3.21: Cancer Biomarker Market Estimates by Tissue of Origin	46	
Table 3.22: Companies Developing New Proteomic Cancer Biomarker Technology Platforms	55	
Table 3.23: Uses of Molecular Diagnostics in Detection and Management of Cancer	57	
Table 3.24: U.S. Cancer Diagnostic Testing Market Size, 2005-2016	58	
Table 3.25: Market Opportunities for Cancer Biomarker Technology Platforms	59	
Table 4.1: Use of Biomarkers in Clinical Use	64	
Table 4.2: Use of Biomarkers in Cancer Research	65	
Table 4.3: Currently Approved Targeted Therapies for Solid Malignancies and Their Molecular Targets	66	
Table 4.4: Tumor Biomarkers Currently in Common Use	68	
Table 4.5: Clinically Relevant Biomarkers	69	
Table 4.6: Biomarkers for Monitoring Therapeutic Effectiveness and Resistance	70	
Table 4.7: Biomarkers for Dose Response of Therapy	71	
Table 4.8: Decision on Optimal Duration of Therapy	71	
Table 5.1: Estimated New Female Breast Cancer Cases and Deaths by Age in the U.S., 2013	75	
Table 5.2: BRCA Development Model	77	
Table 5.3: BRCA Test Development and Commercialization	78	
Table 5.4: BRACAnalysis	78	
Table 5.5: Revenue for BRACAnalysis Risk Assessment Test, 2002-2013	78	
Table 5.6: Key Players in the Breast Cancer Molecular Diagnostic Space	92	
Table 5.7: Companies Offering IVDMA Microarray Breast Cancer Biomarker Analysis	92	
Table 5.8: GEArray DNA Microarrays and RT2 Profiler PCR Arrays	97	
Table 5.9: Product Development Opportunities in Breast Cancer	103	
Table 5.10: Concentration of Some Abundant Proteins, New Cancer Biomarkers Identified by SELDI-TOF and Classical Cancer Biomarkers in Serum	110	
Table 5.11: Questions Related to Diagnostic SELDI-TOF Technology	113	
Table 6.1: Worldwide CA-125 Sales, 2001-2018	119	
Table 6.2: U.S. CA-125 Sales, 2001-2018	120	
Table 6.3: Some Clinically Established Cancer Serum Markers Currently in Use for Cancer	121	
Table 6.4: Pathophysiology of Ovarian Cancer and Characterization of Ovarian Epithelial Tumors	127	
Table 7.1: Worldwide PSA Sales, 2000-2018	129	
Table 7.2: U.S. PSA Sales, 2000-2018	130	
Table 7.3: Molecular Gene Markers for Prostate Cancer	132	
Table 8.1: Worldwide Bladder Cancer Marker Sales, 2001-2018	144	
Table 8.2: U.S. Bladder Cancer Marker Sales, 2001-2018	144	
Table 8.3: Worldwide NMP22 Sales, 2001-2018	145	
Table 8.4: Summary of Matritech's Product Development Programs	146	
Table 8.5: Opportunities for Bladder Cancer Biomarkers	147	
Table 9.1: TNM Staging for CRC	153	
Table 10.1: Genetic Diagnostics Market, 2004-2018	160	
Table 13.1: Genomic and Proteomic Technologies	173	
Table 14.1: Potential Benefits of Biomarkers as Companion Diagnostics	180	
Table 14.2: Utility of Biomarker as Companion Diagnostics to Drug Development	180	
Table 14.3: Device Submission Elements for the FDA	184	
Table 14.4: Summary of Biomarker Use in the Commercialization of Novel Oncology Pharmacotherapeutics	185	
Table 14.5: Pharmacoeconomic Challenges to the Implementation of Biomarkers as Companion Diagnostic Tests	186	
Table 15.1: FDA Approved Companion Diagnostic Devices: <i>In Vitro</i> and Imaging Tools	195	

Table 15.2: Personalized Medicine Industry SWOT Analysis	200	
Table 15.3: Hurdles to Personalized Medicine and Companion Diagnostics Development		201
Table 15.4: Timeline of Impact in Areas of Personalized Medicine	202	
Table 15.5: Impact of Personalized Medicine on Various Therapeutic Areas	203	
Table 15.6: Percentage of Non-Responders in Various Drug Classes	206	
Table 15.7: High Profile Drug Withdrawals from the Marketplace	206	
Table 15.8: Drug Metabolism Drives Drug Efficacy/Toxicity	211	
Table 15.9: Population Frequency of the Various Cytochromes	211	
Table 15.10: Selected List of Personalized Medicine Tests	214	
Table 15.11: Personalized Medicine and Companion Diagnostics Product Pipeline		215
Table 15.12: Marketed Personalized Therapies, 2013	216	
Table 15.13: Members of the Personalized Medicine Coalition	217	
Table 15.14: Various Molecular Diagnostics Technologies: Timeline for Impact		233
Table 15.15: Various Molecular Diagnostics Technologies: Impact on Different Therapeutic Areas in Personalized Medicine	234	
Table 15.16: Technical Challenges in the Deployment for Personalized Medicine		234
Table 15.17: Classification of Diagnostics by Risk	236	
Table 15.18: Areas in Personalized Medicine—Timeline of Impact	239	
Table 15.19: Impact of Personalized Medicine on Various Therapeutic Areas	241	
Table 15.20: Hurdles in Personalized Medicine and Companion Diagnostics Development in Various Therapeutic Areas	241	
Table 15.21: Market Opportunities in Personalized Medicine	244	
Table 15.22: Challenges for Market Adoption of the Various Personalized Medicine Tests		245
Table 15.23: Personalized Medicine Industry SWOT	246	
Table 16.1: List and Discounted Prices for Abbott Tumor Marker Tests	248	
Table 16.2: Increases in Total Allowed Charges for Laboratory Services per Enrollee, 2000-2016		269
Table 16.3: Incurred Reimbursement Amounts per Fee-for-Service for Laboratory Services per Enrollee, 2003-2016	270	
Table 16.4: Medicare Part B Benefit Payments, 2003-2016	270	
Table 17.1: Major GeneChip Instrument Products	282	
Table 17.2: Major GeneChip Array and Reagent Products	282	
Table 17.3: Gene Titan Products	282	
Table 17.4: Gene Atlas Products	283	
Table 17.5: Gene Atlas Products	283	
Table 17.6: Opportunities for Biomarkers in Cancer Diagnosis and Treatment	311	
Table 17.7: Tumor Diagnosis Immunoassay	323	
Table 17.8: Tumor Diagnosis Radioimmunoassay	323	
Table 17.9: Myriad Molecular Diagnostic Revenues, 2012 and 2013	350	
Table 17.10: Roche Group Financial Figures—Net Sales by Business Sector, 2008-2013		370
Table 17.11: Roche Group Diagnostics Division—Net Sales by Geographic Region, 2012 and 2013		370
Table 17.12: Roche Group Financial Figures—Net Sales by Diagnostics Sub-Division, 2008-2013		370
Table A1.1: Team Descriptions	377	
Table A3.1: List of FDA-Approved Protein Tumor Markers Currently Used in Clinical Practice		379

1. Overview

1.1 Statement of Report

The purpose of this report is to describe the specific segment of the cancer diagnostics market that develops and uses new biomarker technology platforms. Such platforms include: IVDMA technology, robotic and automated sample nucleotide extraction and real-time PCR machines, next-generation sequencers, comparative genomic hybridization (CGH) arrays, proteomics and SELDI-TOF-MS technology for cancer biomarker profiling and cancer diagnosis and treatment.

Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study examines those clinical measurement devices and their reagents and supplies that are meant to be used in hospitals, clinics, and commercial laboratories to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in the diagnosis of cancer.

1.2 About This Report

The report describes new technology platforms developed for the analyses of constituents of blood, plasma, serum or tissue that are connected to the growth and progression of cancer. The emphasis is on those companies and products that are actively developing and marketing new clinical laboratory instrumentation, reagents and supplies for performing specific and well-targeted tumor marker tests, as opposed to the more routine and clinically-accepted tumor markers that are manufactured and marketed by large diagnostic companies (*e.g.*, DEA, Ca124, PSA, etc.). This study focuses on biotech companies that have novel new products and procedures in this sector. Research companies in the process of developing new ideas are not reviewed in any detail here.

The main objectives of this analysis are:

- Identifying viable technology drivers for cancer biomarkers and related companion diagnostics through a comprehensive examination of platform technologies, including: IVDMA, probe-based nucleic acid assays, microarrays and sequencing, and mass spectroscopy.
- Obtaining a complete understanding of the new cancer biomarker diagnostic tests—*i.e.*, predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic—from their basic principles to their applications.
- Discovering growing market opportunities by identifying high-growth applications in different cancer diagnostic areas, focusing on the biggest and expanding markets in oncology (*e.g.*, biomarkers for breast cancer and predictive biomarkers).
- Focusing on global industry development through an in-depth analysis of the major world markets for cancer diagnostics, including growth forecasts.

1.3 Scope of the Report

This analysis emphasizes companies that are actively developing and marketing new reagents and supplies for performing cancer biomarker diagnostics tests. It discusses the various market trends and opportunities using new biomarkers, while providing an in-depth analysis of market share, revenue forecasts, and market drivers and restraints. Specialty cancer diagnostics testing, such as pathology screening methods and special tissue stains to examine cancer cells *in situ* are mentioned here, since they are often part of the overall analytical focus of companies that market cancer technology platforms. However, no effort is made to quantify this older and broader market. The reader should consult other TriMark Publications reports at <http://www.trimarkpublications.com> for detailed discussions of important individual market segments related to cancer diagnostics and therapeutics markets, such as *Cancer Diagnostic Testing World Markets*, *Cancer Cell Therapy Markets* and *Cancer Therapeutics Markets*.

1.4 Objectives

The goal of this report is to review the market for new and novel cancer biomarker testing equipment and supplies using reagents and instruments for analysis of individual components in blood, serum or plasma, which depend on the breaking developments in the genomic and proteomic spaces. The study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the specialty CLIA labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The analysis examines:

- Opportunities and barriers for new cancer biomarkers.
- Use of IVDMIA biomarkers in CLIA clinical laboratories which specialize in applying biomarker-based technologies that address critical needs in the management of gynecologic cancers, and that aid in clinical decision making and advanced personalized treatment plans.
- Adaptive design using biomarkers.
- Pharmacodynamic biomarkers identified with broad-based phenotyping as companion diagnostics.
- Tools for improving measurement, safety and validation of biomarkers.
- Filling the gap between discovery and clinically validated biomarkers.
- Enabling technologies for oncology biomarker discovery.

This study answers the following questions:

- Which companies are utilizing cutting-edge technologies to develop, validate and implement cancer biomarkers for clinical use?
- What impediments still exist to incorporating promising research into clinical practice?
- Which cancer biomarkers show the most promise for approval?
- What are the economic challenges to approval?
- How can regulatory oversight drive approval and adoption of new technologies?
- Which alliances show the greatest synergy in bringing valid biomarkers to market?
- Which shared technologies are driving the most encouraging development?

1.5 Methodology

The author of this report holds a PhD in biochemistry from the University of Minnesota and has had post-doctoral experience at the University of Connecticut School of Medicine. He has taught at Quinnipiac University and the Tufts School of Medicine, and has been a senior scientist at Pfizer Pharmaceutical Laboratories in drug development. He also has many decades of experience in science writing and as a medical industry analyst. He has over 30 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboratory director, as well as extensive experience in senior level management positions in biotech and medical service companies. The editor of this report is a PhD in biochemistry from the University of Liverpool and an M.B.A. from Oxford Brookes University in the U.K. with over 35 year's experience in the medical industry, science writing and as a medical industry analyst.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practical, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with

and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly available databases, proprietary databases, direct meetings and personal interviews with key personnel.
- Formulating a study outline with the assigned writer, including important items:
 - Market and product segment grouping and evaluating their relative significance.
 - Key competitors' evaluations including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets. Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Launching a combination of primary research activities including two levels of questionnaires, executive-direct focused, company-specific, and region-specific communications to qualified and experienced senior executives worldwide.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of Expert Panel Partners from the industry being analyzed.

1.6 Executive Summary

Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastasis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer

detection and diagnosis is central to the cancer problem. The use of both nucleic acid and protein biomarker diagnostics has begun to answer these questions.

The cancer biomarker sector is divided into three parts:

- The current market opportunity in the cancer biomarkers space resides almost entirely in the sales of reagents, consumables and services to the clinical oncology community.
- There is also a burgeoning laboratory business emerging in cancer biomarkers, where samples are sent to a central CLIA certified lab for analysis.
- In addition, there are currently a handful of FDA-approved biomarkers for cancer therapeutic agents. There are a number of companies developing biomarkers for various therapeutic segments under the rubric of companion diagnostics.

As the pharmaceutical and diagnostic industries increase the availability of biomarkers, their importance and influence in all aspects of drug discovery and the development process will continue to grow. Co-development of molecular diagnostics and targeted therapeutics has already been proven to be a successful strategy in the development of novel anti-cancer drugs such as Gleevec®.

Although estimates for the value of the global cancer biomarkers market for all applications varies from \$ [redacted] to \$ [redacted] in [redacted], it is clear that the CAGR over the next four to five years will be between [redacted]% and [redacted]%. This rate of growth will ensure that the global biomarkers market value will be about \$ [redacted] by [redacted], and predicted to reach \$ [redacted] by [redacted]. The market could be sub-divided into the following segments based on technological applications. These are: Next-Generation Sequencing (NGS), Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray.

Polymerase chain reaction (PCR)-based diagnostic assays claimed the largest share of the market in [redacted] and has been estimated to be valued at approximately \$ [redacted] in [redacted], and has grown with a CAGR of [redacted]% to reach a market value of \$ [redacted] in [redacted]. At the same predicted CAGR, the market would be predicted to be valued at approximately \$ [redacted] by [redacted]. It is mainly in this sector of the diagnostics market that cancer biomarkers are developed. The potential market for cancer biomarkers is enormous.

Unmet patient need is the major driver of innovation in both cancer diagnostics and therapeutics. There is significant need for high-sensitivity diagnostic methods to detect the presence of early-stage disease. Competitive pressures and reimbursement issues will increase the demand for better diagnostic testing information in order to satisfy the need for a diagnostic component to the clinical decision-making process.

The enormous developments in analytical instrumentation in the last [redacted] years fueled the \$ [redacted] worldwide biotechnology instrumentation market in [redacted], of which the U.S. biotechnology instrumentation market was estimated to be \$ [redacted]. Of course, the deoxyribonucleic acid (DNA) revolution has brought an entire new class of analytical instruments on board in the last [redacted] years. DNA structure and function has lead to new classes of cancer markers.

The cancer biomarkers space can be sub-divided into roughly three types, primarily based on their usage:

- *Routine Blood-based Traditional Markers such as CEA, PSA, CA-125, etc.:* These traditional tumor markers have been in clinical use for over [redacted] years (CEA was introduced by Dr. Phil Gold in [redacted]). These constitute a steadily growing market of \$ [redacted] worldwide.
- *New Tissue-Specific Cancer Biomarkers based on Proteomics and Molecular Diagnostics:* This is a new area that develops markers for early detection of cancer, assesses outcomes, and predicts recurrence. This is the segment with the largest potential market opportunity.

- *Companion Diagnostic Tests Developed in Conjunction with Therapeutic Agents:* The use of diagnostic tests to follow the progress of clinical trials, and later to assess efficacy for patient populations receiving anti-cancer therapeutics, is growing rapidly. The deployment of cancer biomarkers in preclinical Research & Development (R&D) as a tool to assess lead compound toxicity, as well as assess toxicity or efficacy (such as hERG toxicity screening) exists today. Products and services offered into this market are: toxicity screening in drug discovery and development using cancer biomarkers, reagents, media, cells, consumables and miscellaneous services.

Targeted therapies have revolutionized the way cancer is being treated (Personalized Medicine), opening up the possibility that many forms of the disease can be fought through long-term maintenance therapy. These therapies are helping to win individual battles against cancer, enabling us to think of it as a chronic illness, rather than a life-ending one. With the industry's innovation and ongoing scientific advances, growth in targeted therapies will continue to be very strong and the outcomes even more impressive, and this will drive the development of companion diagnostic tests. Cancer testing is one of the most important growth opportunities in the diagnostics segment for the next three to five years.

The efforts to diagnose cancer and other complex diseases have failed in large part because the disease is heterogeneous at the causative level (*i.e.*, most diseases can be traced to multiple potential etiologies) and at the human response level (*i.e.*, each individual afflicted with a given disease can respond to that ailment in a specific manner). Consequently, measuring a single protein biomarker when multiple protein biomarkers may be altered in a complex disease is unlikely to provide meaningful information about the disease state. The market for advanced cancer diagnostic testing will increase to over \$ [REDACTED] by [REDACTED]. This increase is attributable to multiple factors including increasing incidences of cancer in an aging population, new therapies and expanded testing panels. The patient market for breast cancer exceeds \$ [REDACTED] per year (although most of this is associated with mammography screening) and for cervical cancer testing exceeds \$ [REDACTED] per year.

By [REDACTED], [REDACTED] or so companies have developed proprietary molecular based cancer tests that were at or very near market. The market for these tests is getting very competitive, and some companies are finding out that even as a service, the test really has to respond to medical needs or the technological norms of routine laboratories. Case in point is Agendia's MammaPrint breast cancer test for cancer recurrence that has had limited success, and this in spite of having FDA clearance.

Other test services that have been launched include Bio Reference Laboratories' test for K-RAS mutation in the colon, Fujirebio Diagnostic's HE4 Ovarian Cancer Test, Rosetta Genomics' miRview meso for mesothelioma, Clariant's Prostate Gene Expression Profile, Neogenomics Laboratories' FISH probe service for melanoma, and Acupath Laboratories' test for bladder cancer genes.

In [REDACTED], CLIA-certified laboratories were operated by a diverse range of companies, including Affymetrix, CombiMatrix, deCode Genetics, Diagnocure, Ikonisys, Illumina, Predictive Biosciences, Sequenom, Siemens Diagnostics, and Xceed Molecular. These firms market their tests or technology platforms as commercial products and also offer testing services to other laboratories. Several companies established CLIA-certified laboratories for cancer testing, including Agendia, Beckman Coulter, bioMérieux, Sequenom and Celera Diagnostics.